TECH - Bio-Techne Corporation
| Previous close | 260.65 |
| Open | 257.74 |
| Bid | 0.00 x 1200 |
| Ask | 258.25 x 1000 |
| Day's range | 245.46 - 258.23 |
| 52-week range | 155.17 - 282.52 |
| Volume | 291,267 |
| Avg. volume | 303,282 |
| Market cap | 9.706B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | 54.09 |
| EPS (TTM) | 4.76 |
| Earnings date | 04 Aug 2020 - 10 Aug 2020 |
| Forward dividend & yield | 1.28 (0.49%) |
| Ex-dividend date | 08 May 2020 |
| 1y target est | 241.50 |
- Motley Fool
Bio-Techne Corp (TECH) Q3 2020 Earnings Call Transcript
On the call with me this morning are Chuck Kummeth, Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne. The company's 10-K for fiscal year 2019 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during this call.
- Zacks
Earnings Preview: Techne (TECH) Q3 Earnings Expected to Decline
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
REGN vs. TECH: Which Stock Should Value Investors Buy Now?
REGN vs. TECH: Which Stock Is the Better Value Option?
- Zacks
Techne (TECH) Lags Q2 Earnings and Revenue Estimates
Techne (TECH) delivered earnings and revenue surprises of -5.26% and -3.50%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
GILD vs. TECH: Which Stock Should Value Investors Buy Now?
GILD vs. TECH: Which Stock Is the Better Value Option?
- Yahoo Finance
Premium Millennial Generation Portfolio
There are now more than 80 million Millennials, born between 1982 and 2000 and ranging in age from their early 20s to their late-30s. This generation is the largest in history – bigger than even the Baby Boomers. According to our research, Millennials currently account for 24% of total U.S income – some $2.9 trillion in direct annual purchasing power, mostly representing older Millennials established in their work and families. The intersection of several trends – sustainability, healthier living, and an entrepreneurial spirit – has resulted in the emergence and growth of numerous companies well-suited to the millennial generation. The Argus Millennial Generation portfolio consists of 30 stocks that fit many of these themes.
- Zacks
CELG vs. TECH: Which Stock Is the Better Value Option?
CELG vs. TECH: Which Stock Is the Better Value Option?
- Zacks
Techne (TECH) Q1 Earnings Lag Estimates
Techne (TECH) delivered earnings and revenue surprises of -0.93% and 1.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
New Strong Sell Stocks for August 15th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
- Zacks
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Motley FoolBio-Techne Corp (TECH) Q4 2019 Earnings Call Transcript
TECH earnings call for the period ending August 6, 2019.
- Zacks
Techne (TECH) Q4 Earnings and Revenues Lag Estimates
Techne (TECH) delivered earnings and revenue surprises of -4.58% and -3.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2?
Within the Health Care Benefits segment, CVS Health (CVS) expects the government programs to go from strength to strength on the back of Medicare growth and major Medicaid wins.
- Zacks
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
Better-than-expected performance at Pharmaceutical and Medical segments are likely to aid Cardinal Health's (CAH) in Q4 earnings.
- Zacks
Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?
Henry Schein (HSIC) is working diligently to grow in the field of digital dentistry, globally.
- Zacks
Can Patient Wins Aid GW Pharmaceuticals (GWPH) Q2 Earnings?
GW Pharmaceuticals (GWPH) is witnessing a solid new patient recruitment for Epidolex and a huge number of physicians are recommending the same in their prescriptions.
- Zacks
Can Bruker (BRKR) Q2 Earnings See BioSpin's Growth Revival?
Bruker (BRKR) expects BioSpin to bode well for better organic growth in Q2.
- Zacks
CBM or TECH: Which Is the Better Value Stock Right Now?
CBM vs. TECH: Which Stock Is the Better Value Option?
- Zacks
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Zacks
Why the Earnings Surprise Streak Could Continue for Techne (TECH)
Techne (TECH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
- Zacks
Myriad Genetics Announces Study Results Of myRisk Cancer Test
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
